Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak

Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.

    Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences

    Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences

      Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

      Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

        5 Discounted PEG Stocks for GARP Investors

        PEG ratio is categorized under value investing and follows the principles of both growth and value investing.

          Arpita Dutt headshot

          Forget Teva (TEVA), Buy These 4 Drug Stocks Instead

          With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.

            Supriyo Bose headshot

            Markets Remain Choppy on Continuing Conflicts: 5 Top Picks

            ROE helps investors distinguish between profit-generating companies from profit burners and is useful for determining the financial health of a company.

              Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss

              Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.

                Top Ranked Income Stocks to Buy for August 10th

                Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 10th:

                  Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View

                  Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.

                    Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View

                    Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.

                      Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

                      Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

                        Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak

                        Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.

                          Arpita Dutt headshot

                          Forget Bayer, Buy These 3 Drug Stocks Instead

                          With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.

                            Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

                            A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.

                              Top Ranked Momentum Stocks to Buy for August 7th

                              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:

                                Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                                Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

                                  Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses

                                  Radius Health, Inc. (RDUS) posted a wider-than-expected loss in the second quarter due to an increase in general and administrative expenses.

                                    Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View

                                    Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.

                                      Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2

                                      Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.

                                        Top Ranked Income Stocks to Buy for August 2nd

                                        Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 2nd:

                                          Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2

                                          Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.

                                            United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

                                            United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

                                              Arpita Dutt headshot

                                              4 Drug Stocks in Focus this World Hepatitis Day

                                              Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

                                                Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

                                                Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

                                                  Ryan McQueeney headshot

                                                  Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats

                                                  Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion.